Replies to post #122990 on Biotech Values

[genisi]

Tell me about it, I need to explain that to my mother in law, who is on the drug.

[mcbio]

Multaq has been a big disappointment.

Does this news benefit CRME and vernakalant? Perhaps not, since I know CRME has their own outstanding issues with I.V. vernakalant (#msg-55777710 ) to go along with to what extent, if truly any, Merck will proceed with the oral version of the drug.

I realize CRME's valuation is depressed a bit, but I'm normally not keen on backing a company with pretty much just one drug, especially when that one drug has some question marks around safety.